{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:04:57Z","timestamp":1791396297718,"version":"4.3.3"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The ubiquitin-proteasome system (UPS) is an intracellular organelle responsible for targeted protein degradation, which represents a standard therapeutic target for many different human malignancies. Bortezomib, a reversible inhibitor of chymotrypsin-like proteasome activity, was first approved by the FDA in 2003 to treat multiple myeloma and is now used to treat a number of different cancers, including relapsed mantle cell lymphoma, diffuse large B-cell lymphoma, colorectal cancer, and thyroid carcinoma. Despite the success, bortezomib and other proteasome inhibitors are subject to severe side effects, and ultimately, drug resistance. We recently reported an oncogenic role for non-ATPase members of the 19S proteasome in chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and several different solid tumors. In the present study, we hypothesized that ATPase members of the 19S proteasome would also serve as biomarkers and putative therapeutic targets in AML and multiple other cancers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used data from The Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) available at UALCAN and\/or GEPIA2 to assess the expression and prognostic value of proteasome 26S subunit, ATPases 1-6 (PSMC1-6) of the 19S proteasome in cancer. UALCAN was also used to associate <jats:italic>PSMC1<\/jats:italic>-6 mRNA expression with distinct clinicopathological features. Finally, cBioPortal was employed to assess genomic alterations of <jats:italic>PSMC<\/jats:italic> genes across different cancer types.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mRNA and protein expression of <jats:italic>PSMC1<\/jats:italic>-6 of the 19S proteasome were elevated in several cancers compared with normal controls, which often correlated with worse overall survival. In contrast, AML patients demonstrated reduced expression of these proteasome subunits compared with normal mononuclear cells. However, AML patients with high expression of <jats:italic>PSMC2<\/jats:italic>-5 had worse outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Altogether, our data suggest that components of the 19S proteasome could serve as prognostic biomarkers and novel therapeutic targets in AML and several other human malignancies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1209425","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T20:03:26Z","timestamp":1689192206000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["The prognostic value of 19S ATPase proteasome subunits in acute myeloid leukemia and other forms of cancer"],"prefix":"10.3389","volume":"10","author":[{"given":"Boranai","family":"Tychhon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse C.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra A.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idaly M.","family":"Olivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Solecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrshad","family":"Keivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa V.","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B.","family":"McCall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree N.","family":"Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres J.","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Eiring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","article-title":"The logic of the 26S proteasome","volume":"169","author":"Collins","year":"2017","journal-title":"Cells"},{"key":"ref2","first-page":"4167","article-title":"UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme","volume":"63","author":"Okamoto","year":"2003","journal-title":"Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbamcr.2004.09.019","article-title":"Ubiquitin: structures, functions, mechanisms","volume":"1695","author":"Pickart","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.sbi.2020.10.010","article-title":"Mechanisms of substrate recognition by the 26S proteasome","volume":"67","author":"Davis","year":"2021","journal-title":"Curr Opin Struct Biol"},{"key":"ref5","first-page":"469","article-title":"New insights into the role of the ubiquitin-proteasome pathway in the regulation of apoptosis","volume":"30","author":"Liu","year":"2007","journal-title":"Chang Gung Med J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.dnarep.2009.01.017","article-title":"Damage control: DNA repair, transcription, and the ubiquitin-proteasome system","volume":"8","author":"Daulny","year":"2009","journal-title":"DNA Repair"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"821839","DOI":"10.3389\/fcell.2021.821839","article-title":"The gentle side of the UPS: ubiquitin-proteasome system and the regulation of the myogenic program","volume":"9","author":"Olgu\u00edn","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nrc2396","article-title":"Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer","volume":"8","author":"Frescas","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3390\/cells11071093","article-title":"Modulating the ubiquitin-proteasome system: a therapeutic strategy for autoimmune diseases","volume":"11","author":"Yadav","year":"2022","journal-title":"Cells"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.2147\/DDDT.S265793","article-title":"Proteasome, a promising therapeutic target for multiple diseases beyond Cancer","volume":"14","author":"Cao","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1158\/1535-7163.MCT-11-0745","article-title":"Bortezomib: understanding the mechanism of action","volume":"10","author":"Piperdi","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3390\/cancers12040902","article-title":"Drug development targeting the ubiquitin-proteasome system (UPS) for the treatment of human cancers","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.2147\/OTT.S317570","article-title":"Efficacy and toxicity profile of carfilzomib-based regimens for treatment of newly diagnosed multiple myeloma: a systematic review","volume":"14","author":"Imtiaz","year":"2021","journal-title":"Onco Targets Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"112068","DOI":"10.1016\/j.biopha.2021.112068","article-title":"The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy","volume":"142","author":"Yan","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.2147\/CMAR.S150653","article-title":"Carfilzomib for relapsed and refractory multiple myeloma","volume":"11","author":"Groen","year":"2019","journal-title":"Cancer Manag Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1111\/febs.12814","article-title":"A novel role for the proteasomal chaperone PSMD9 and hnRNPA1 in enhancing I\u03baB\u03b1 degradation and NF-\u03baB activation - functional relevance of predicted PDZ domain-motif interaction","volume":"281","author":"Sahu","year":"2014","journal-title":"FEBS J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2014.11.002","article-title":"Deubiquitinase inhibition as a cancer therapeutic strategy","volume":"147","author":"D'Arcy","year":"2015","journal-title":"Pharmacol Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1073\/pnas.1120559109","article-title":"Molecular architecture of the 26S proteasome holocomplex determined by an integrative approach","volume":"109","author":"Lasker","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature10774","article-title":"Complete subunit architecture of the proteasome regulatory particle","volume":"482","author":"Lander","year":"2012","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/onc.2013.60","article-title":"DNA damage emergency: cellular garbage disposal to the rescue?","volume":"33","author":"Stone","year":"2014","journal-title":"Oncogene"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fmolb.2019.00040","article-title":"Dynamic regulation of the 26S proteasome: from synthesis to degradation","volume":"6","author":"Marshall","year":"2019","journal-title":"Front Mol Biosci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.tibs.2012.11.009","article-title":"Functions of the 19S complex in proteasomal degradation","volume":"38","author":"Liu","year":"2013","journal-title":"Trends Biochem Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2183\/pjab.85.12","article-title":"The proteasome: overview of structure and functions","volume":"85","author":"Tanaka","year":"2009","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.3390\/cells10092390","article-title":"26S proteasome non-ATPase regulatory subunits 1 (PSMD1) and 3 (PSM3) as putative targets for cancer prognosis and therapy","volume":"10","author":"Rubio","year":"2021","journal-title":"Cells"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"14586","DOI":"10.3390\/ijms232314586","article-title":"19S proteasome subunits as oncogenes and prognostic biomarkers in FLT3-mutated acute myeloid leukemia (AML)","volume":"23","author":"Lara","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/biom11010060","article-title":"The ubiquitin-proteasome system in immune cells","volume":"11","author":"Cetin","year":"2021","journal-title":"Biomol Ther"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system","volume":"14","author":"Dou","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10555-017-9699-4","article-title":"(Immuno)proteasomes as therapeutic target in acute leukemia","volume":"36","author":"Cloos","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41375-020-0989-4","article-title":"Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma","volume":"35","author":"Allmeroth","year":"2021","journal-title":"Leukemia"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1158\/1541-7786.MCR-19-1026","article-title":"Proteasome subunits differentially control myeloma cell viability and proteasome inhibitor sensitivity","volume":"18","author":"Shi","year":"2020","journal-title":"Mol Cancer Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF00990967","article-title":"Subunits of the regulatory complex of the 26S protease","volume":"21","author":"Dubiel","year":"1995","journal-title":"Mol Biol Rep"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-biophys-083012-130417","article-title":"Structural biology of the proteasome","volume":"42","author":"Kish-Trier","year":"2013","journal-title":"Annu Rev Biophys"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nrm3741","article-title":"Regulated protein turnover: snapshots of the proteasome in action","volume":"15","author":"Bhattacharyya","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1021\/bi400417a","article-title":"Structural insights into proteasome activation by the 19S regulatory particle","volume":"52","author":"Ehlinger","year":"2013","journal-title":"Biochemistry"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/ncb3289","article-title":"Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis","volume":"18","author":"Guo","year":"2016","journal-title":"Nat Cell Biol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ccr.2013.11.001","article-title":"A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13\/ADRM1 as a therapy for cancer","volume":"24","author":"Anchoori","year":"2013","journal-title":"Cancer Cell"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/leu.2016.97","article-title":"Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma","volume":"30","author":"Song","year":"2016","journal-title":"Leukemia"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"15540","DOI":"10.1038\/ncomms15540","article-title":"Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets","volume":"8","author":"Lu","year":"2017","journal-title":"Nat Commun"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"9493","DOI":"10.1074\/jbc.M117.785287","article-title":"Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism","volume":"292","author":"VanderLinden","year":"2017","journal-title":"J Biol Chem"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"9659","DOI":"10.1074\/jbc.AC119.008881","article-title":"Phosphorylation of Tyr-950 in the proteasome scaffolding protein RPN2 modulates its interaction with the ubiquitin receptor RPN13","volume":"294","author":"Hemmis","year":"2019","journal-title":"J Biol Chem"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1038\/s41375-019-0467-z","article-title":"Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma","volume":"33","author":"Song","year":"2019","journal-title":"Leukemia"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41408-020-00398-9","article-title":"Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1\/Rpn13","volume":"11","author":"Song","year":"2021","journal-title":"Blood Cancer J"},{"key":"ref45","first-page":"1371","article-title":"Physical and functional analysis of the putative Rpn13 inhibitor RA190. Cell","volume":"27","author":"Dickson","year":"2020","journal-title":"Chem Biol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e00122","DOI":"10.1128\/MCB.00122-20","article-title":"Impact of losing hRpn13 Pru or UCHL5 on proteasome clearance of Ubiquitinated proteins and RA190 cytotoxicity","volume":"40","author":"Osei-Amponsa","year":"2020","journal-title":"Mol Cell Biol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s12885-020-06896-0","article-title":"Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-kappaB signaling","volume":"20","author":"Soong","year":"2020","journal-title":"BMC Cancer"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1159\/000490210","article-title":"RA190, a proteasome subunit ADRM1 inhibitor, suppresses intrahepatic cholangiocarcinoma by inducing NF-KB-mediated cell apoptosis","volume":"47","author":"Yu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1038\/s41388-021-01732-6","article-title":"Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B","volume":"40","author":"Bencomo-Alvarez","year":"2021","journal-title":"Oncogene"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejphar.2016.03.031","article-title":"Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer","volume":"780","author":"Boland","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3390\/cancers11040527","article-title":"Proteasome 26S subunit, non-ATPase 3 (PSMD3) regulates breast Cancer by stabilizing HER2 from degradation","volume":"11","author":"Fararjeh","year":"2019","journal-title":"Cancers"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/jb\/mvx053","article-title":"Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation","volume":"163","author":"Okumura","year":"2018","journal-title":"J Biochem"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1017866","DOI":"10.3389\/fgene.2022.1017866","article-title":"Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma","volume":"13","author":"Jia","year":"2022","journal-title":"Front Genet"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"935286","DOI":"10.3389\/fgene.2022.935286","article-title":"Evaluating the prognostic and therapeutic potentials of the proteasome 26S subunit, ATPase (PSMC) family of genes in lung adenocarcinoma: a database mining approach","volume":"13","author":"Ullah","year":"2022","journal-title":"Front Genet"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"17970","DOI":"10.18632\/aging.203345","article-title":"Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer","volume":"13","author":"Kao","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3390\/cancers15020532","article-title":"Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma","volume":"15","author":"Haertle","year":"2023","journal-title":"Cancers"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bbabio.2008.12.019","article-title":"P-type ATPases as drug targets: tools for medicine and science","volume":"1787","author":"Yatime","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000091298","article-title":"Acid suppression therapy: where do we go from here?","volume":"24","author":"Scarpignato","year":"2006","journal-title":"Dig Dis"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1002\/cam4.1594","article-title":"Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer","volume":"7","author":"Whitton","year":"2018","journal-title":"Cancer Med"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's oncology group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/pcan.2010.48","article-title":"Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma","volume":"14","author":"Hellwinkel","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/cdd.2011.128","article-title":"TRAP1 and the proteasome regulatory particle TBP7\/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins","volume":"19","author":"Amoroso","year":"2012","journal-title":"Cell Death Differ"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3892\/ijo.2013.2199","article-title":"TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells","volume":"44","author":"Sisinni","year":"2014","journal-title":"Int J Oncol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"24881","DOI":"10.1073\/pnas.1912033116","article-title":"Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression","volume":"116","author":"Banerjee","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12935-020-01317-5","article-title":"A novel risk score system of immune genes associated with prognosis in endometrial cancer","volume":"20","author":"Zhou","year":"2020","journal-title":"Cancer Cell Int"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3389\/fgene020.00725","article-title":"Prognostic implications of immune-related Genes' (IRGs) signature models in cervical Cancer and endometrial Cancer","volume":"11","author":"Ding","year":"2020","journal-title":"Front Genet"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1186\/s12935-020-01560-w","article-title":"Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma","volume":"20","author":"Zhou","year":"2020","journal-title":"Cancer Cell Int"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/CCI.21.00094","article-title":"Novel insight into the association between obesity and hepatocellular carcinoma occurrence and recurrence: high-throughput microarray data set analysis of differentially expressed genes","volume":"5","author":"Hassani","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"6389906","DOI":"10.1155\/2022\/6389906","article-title":"Genetic cross-talk between Oral squamous cell carcinoma and type 2 diabetes: the potential role of immunity","volume":"2022","author":"Fan","year":"2022","journal-title":"Dis Markers"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1031210","DOI":"10.3389\/fendo.2022.1031210","article-title":"Proteomics analysis of cancer tissues identifies IGF2R as a potential therapeutic target in laryngeal carcinoma","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1038\/onc.2009.264","article-title":"Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2)","volume":"28","author":"Arlt","year":"2009","journal-title":"Oncogene"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"e08467","DOI":"10.7554\/eLife.08467","article-title":"Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome","volume":"4","author":"Tsvetkov","year":"2015","journal-title":"Elife"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1209425\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T20:03:33Z","timestamp":1689192213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1209425\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":77,"alternative-id":["10.3389\/fmed.2023.1209425"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1209425","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"article-number":"1209425"}}